Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US10112942 | LOXO ONCOL ELI LILLY | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors |
Oct, 2037
(13 years from now) | |
US10584124 | LOXO ONCOL ELI LILLY | Crystalline forms |
Oct, 2038
(14 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10172851 | LOXO ONCOL ELI LILLY | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors |
Oct, 2037
(13 years from now) | |
US10137124 | LOXO ONCOL ELI LILLY | Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors |
Oct, 2037
(13 years from now) | |
US10786489 | LOXO ONCOL ELI LILLY | Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carbonitrile |
Oct, 2038
(14 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | May 08, 2025 |
Orphan Drug Exclusivity(ODE-301) | May 08, 2027 |
Orphan Drug Exclusivity(ODE-303) | May 08, 2027 |
Orphan Drug Exclusivity(ODE-302) | May 08, 2027 |
Orphan Drug Exclusivity(ODE-409) | Sep 21, 2029 |
Orphan Drug Exclusivity(ODE-412) | Sep 21, 2029 |
NCE-1 date: 08 May, 2024
Market Authorisation Date: 08 May, 2020
Treatment: Treatment of adult patients with metastatic ret fusion-positive non-small cell lung cancer; Treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic medullary th...
Dosage: CAPSULE;ORAL